SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

9 Apr 2013 07:00

RNS Number : 8085B
Victrex PLC
09 April 2013
 



Victrex plc

 

Half Year Trading Update

 

The Company announces its trading update for the six months ended 31 March 2013.

 

Trading

We are pleased to report that, despite continued global economic challenges, Group sales volume for the first half of 1,392 tonnes was ahead of the same period for last year (1,377 tonnes). As expected, this reflects a stronger performance from our Victrex Polymer Solutions business ('VPS') in the second quarter with Group sales volume of 752 tonnes compared to the first quarter of 640 tonnes. The first half has also seen continued progress from speciality products, predominantly driven by success in our Aptiv® films business.

 

In our Invibio® Biomaterial Solutions business ('Invibio') the de-stocking we reported at selected spine customers in the second half of last year has continued resulting in revenues for the first half of £24.2m compared to £25.5m for the same period last year. We have made further progress with regulatory approvals in the spine market in Asia and the initial response to the launch of our dental product line, JUVORATM, has been positive.

 

Management appointment

We are pleased to report the appointment of Dr Martin Court as Managing Director of our Invibio business. Prior to joining Victrex, Martin was Vice President of In Process Separation at Cytec Industries Inc. Martin brings a wealth of experience to the management team having held senior strategic, international, general management and technical roles within Cytec, UCB and ICI.

 

Outlook

We remain vigilant of the challenges that persist in some of our end markets, however the initial order book for April is robust.

 

The opportunities to drive growth into new markets, applications and geographies remain strong. We continue to work with customers and end users on focused application development and our key growth programmes to ensure the potential for our business is realised.

 

Our capital investment programme remains on track, including our Victrex PEEK capacity expansion as well as projects to further develop our capability in downstream processing such as film, pipes and composites.

 

 

Victrex will host a conference call at 9.00am today for analysts. If you would like more details, please contact Rosa Smith at MHPC on 0203 128 8560 / Rosa.Smith@mhpc.com.

 

Victrex will announce its results for the six months ended 31 March 2013 on Tuesday 28 May 2013.

 

Enquiries

 

Victrex plc

Steve Barrow, Finance Director 0203 128 8100 (9 April 2013)

01253 897700 (thereafter)

 

MHP Communications

Nick Denton / Barnaby Fry / Ian Payne 0203 128 8100

 

Victrex plc is an innovative world leader in high performance materials through the manufacture of VICTREX® PEEK polymer, a high performance, easy to process thermoplastic.

 

With over 30 years of experience, Victrex is a provider of innovative, high performance thermoplastic polymers. We work with customers and end users globally to deliver technology driven solutions to the challenges and opportunities they face. Our Victrex Polymer Solutions business unit ('VPS') focuses on our transport, industrial and electronics markets and our Invibio® Biomaterial Solutions business unit ('Invibio') focuses on providing specialist solutions for medical device manufacturers.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGUWCCUPWGGR
Date   Source Headline
30th Jun 20251:38 pmRNSTotal Voting Rights
30th Jun 20259:13 amRNSDirector Declaration
18th Jun 20257:00 amRNSAppointment of Joint Corporate Broker
3rd Jun 20251:56 pmRNSHolding(s) in Company
2nd Jun 202511:34 amRNSBlock listing Interim Review
2nd Jun 202510:25 amRNSHolding(s) in Company
30th May 20259:50 amRNSTotal Voting Rights
27th May 202512:40 pmRNSHolding(s) in Company
13th May 20253:30 pmRNSDirector/PDMR Shareholding
12th May 20257:00 amRNSVictrex plc – Interim Results 2025
7th May 20257:00 amRNS‘Magma’ advances via TechnipFMC award
30th Apr 202511:00 amRNSTotal Voting Rights
31st Mar 20259:17 amRNSTotal Voting Rights
21st Mar 202510:34 amRNSDirector/PDMR Shareholding
28th Feb 20259:55 amRNSTotal Voting Rights
19th Feb 20259:00 amRNSAdditional Listing
7th Feb 20251:54 pmRNSResult of AGM
7th Feb 20257:00 amRNSAGM and Trading Update
31st Jan 20259:17 amRNSTotal Voting Rights
21st Jan 20251:56 pmRNSHolding(s) in Company
6th Jan 20251:00 pmRNSAnnual Financial Report
31st Dec 20249:00 amRNSTotal Voting Rights
16th Dec 20248:52 amRNSDirector/PDMR Shareholding
11th Dec 20243:07 pmRNSDirector/PDMR Shareholding
10th Dec 202411:46 amRNSDirector/PDMR Shareholding
10th Dec 20249:28 amRNSHolding(s) in Company
3rd Dec 202410:58 amRNSDirector/PDMR Shareholding
3rd Dec 20247:00 amRNSVictrex plc - Preliminary Results 2024
2nd Dec 20249:38 amRNSBlock listing Interim Review
29th Nov 20249:07 amRNSTotal Voting Rights
14th Nov 20249:31 amRNSHolding(s) in Company
31st Oct 202412:25 pmRNSTotal Voting Rights
14th Oct 20243:09 pmRNSHolding(s) in Company
30th Sep 20241:44 pmRNSTotal Voting Rights
27th Sep 20249:22 amRNSHolding(s) in Company
24th Sep 202411:24 amRNSDirector/PDMR Shareholding
17th Sep 20242:00 pmRNSUS FDA approval: Total Knee Study
12th Sep 202411:18 amRNSDirector/PDMR Shareholding
3rd Sep 20244:20 pmRNSHolding(s) in Company
30th Aug 20243:44 pmRNSDirector/PDMR Shareholding
30th Aug 20249:16 amRNSTotal Voting Rights
23rd Aug 20243:18 pmRNSHolding(s) in Company
9th Aug 202410:08 amRNSHolding(s) in Company
5th Aug 20241:56 pmRNSDirector/PDMR Shareholding
2nd Aug 202411:51 amRNSDirector/PDMR Shareholding
1st Aug 20241:20 pmRNSDirector/PDMR Shareholding
31st Jul 202412:20 pmRNSTotal Voting Rights
5th Jul 20242:02 pmRNSDirector/PDMR Shareholding
4th Jul 20247:00 amRNSQ3 Interim Management Statement
28th Jun 20249:52 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.